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Pathology due to the immune system’s response to viral infections often represents a delicate balance
between inhibition of viral pathogenesis and regulation of protective immunity. In susceptible C57BL/6 (B6)
mice, the murine retroviral isolate LP-BM5 induces splenomegaly, hypergammaglobulinemia, profound B- and
T-cell immunodeficiency, and increased susceptibility to opportunistic pathogens and terminal B-cell lymphomas. Here, we report that B6.PD-1 (programmed death-1) and B6.IL-10 knockout mice are substantially more
susceptible to LP-BM5-induced disease than wild-type B6 mice. LP-BM5-infected B6.PD-1ⴚ/ⴚ mice developed
more severe splenomegaly, hypergammaglobulinemia, and immunodeficiency than infected B6 mice: PD-1ⴚ/ⴚ
mice are more susceptible to lower doses of LP-BM5 and show more exaggerated disease early postinfection.
LP-BM5-infected B6.IL-10ⴚ/ⴚ mice also develop exaggerated LP-BM5-induced disease, compared to B6 mice,
without a significant change in the retroviral load. By reciprocal reconstitution experiments, comparing
wild-type versus PD-1ⴚ/ⴚ sources of the requisite cells for LP-BM5 pathogenesis—CD4 T and B cells, PD-1ⴙ
B cells appear to be crucial in the normal limitation of LP-BM5-induced disease in B6 mice. Also, infected B6
mice have increased CD11bⴙ spleen cells that express interleukin-10 (IL-10). However, PD-1ⴚ/ⴚ mice, though
showing an even greater expansion of CD11bⴙ cells after LP-BM5 inoculation, did not show an equivalent
increase in IL-10-producing cells. Thus, it appears that PD-1/PD-L interactions and IL-10 are primarily
important in moderating the effects of LP-BM5-induced disease in B6 mice.
molecules such as PD-1 may unwittingly augment not only
protective antiviral T-cell immunity but also T-cell responses
that contribute to pathogenesis.
After infection with the LP-BM5 murine leukemia retrovirus
isolate, a disease syndrome which includes profound immunodeficiency develops in certain inbred strains of mice such as the
highly susceptible C57BL/6 (B6) strain (3, 11, 26, 28, 47). By
about 3 weeks postinfection (wpi) with LP-BM5, activationrelated events, which include hypergammaglobulinemia (hyperIg) and splenomegaly, become easily detectable in LP-BM5-infected B6 mice. Beginning at approximately 6 wpi, a profound
immunodeficiency is readily apparent, including severely dampened T- and B-cell responses, leading to the full array of disease
features (8, 10, 33, 34, 40, 46, 48, 54, 66). Thus, there is an
increased susceptibility to disease progression and death when
mice are exposed to environmental pathogens that normally
cause limited infections, and at later time points LP-BM5infected B6 mice develop B-cell lymphomas. Many of the disease features of this murine retrovirus-induced immunodeficiency disease are similar to those that afflict individuals with
HIV/AIDS (4, 43, 49).
Inoculation of LP-BM5 into B6 mice genetically deficient in or
subjected to prior in vivo depletion of either CD4⫹ T cells or B
cells leads to infection but not to virus-induced disease (10, 22, 23,
41, 42, 66, 73). To further characterize the requirement for these
lymphoid subsets, we determined that CD154/CD40 interactions
are necessary for both the induction and progression of LP-BM5
pathogenesis. In vivo treatment with anti-CD154 (CD40 ligand)
monoclonal antibody (MAb) either at the initiation of or 3 to 4

While neutralizing antibody responses are often critical
upon virus reinfection, or in response to an initial virus challenge following analogous vaccination, cell-mediated immunity
also frequently plays an important role in protection. CD8⫹
T-cell effector responses in particular, but also CD4⫹ T cells
that mediate T-cell help and/or serve as effectors themselves,
can be crucially important in protecting against, or limiting the
extent of, viral infections. Cell-mediated immunity is especially
relevant during the time span before high-titer, high-affinity
neutralizing antibody responses may be generated. Recently, it
has become apparent during several chronic viral infections,
including human immunodeficiency virus (HIV)/AIDS, that
normal immune down-regulating mechanisms, such as the programmed death-1 (PD-1) pathway, may be a crucial factor in
limiting the magnitude or duration of antiviral T-cell responses, such that virus is not cleared or controlled. Strategies
to inhibit such negative regulation, and thereby improve protective T-cell immunity, are therefore attractive. However, responses by T cells can also be responsible for the immunopathology observed in many disease states, including viral
infections. Thus, an understudied possibility is that interventions to abrogate or diminish negative regulation by inhibitory
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weeks after infection of B6 mice led to substantial inhibition of
splenomegaly, hyper-Ig, and B- and T-cell immunodeficiency (21,
22). As confirmation of a requirement for a CD154/CD40 molecular interaction for LP-BM5-induced disease, we and others have
reported that, compared to wild-type (WT) B6 mice, B6.CD154
(23) and CD40 (23, 74) knockout (KO) mice are resistant to
LP-BM5-induced disease. Further, by reciprocal adoptive-transfer experiments, we directly demonstrated that CD4⫹ T cells and
B cells are necessary, respectively, for the requisite CD154 and
CD40 expression in LP-BM5-induced disease (23). Prompted by
studies showing that CD154 oligomerization of CD40 results in
the recruitment of cytoplasmic TRAF (tumor necrosis factor receptor-associated factor) proteins to the classic shared
TRAF2,3/5 versus TRAF6 binding sites of the CD40 cytoplasmic
tail domain (37, 56, 57), our laboratory has also reported that
LP-BM5-induced disease depends specifically on CD40-TRAF6
signaling (20). However, the paradigm that the functional consequences of ligation of CD40 on B cells, via a number of overlapping signal transduction pathways, often ultimately are dependent
on the well-known downstream up-regulation of the costimulatory ligands for CD28 and CTLA-4, i.e., B7-1 (CD80) and B7-2
(CD86) (9, 32, 58, 59, 61), does not appear to explain LP-BM5
disease. Thus, we showed that B6.CD80/CD86 double-KO mice
were susceptible to LP-BM5-induced disease (24). Therefore,
CD154 ligation of CD40 in LP-BM5-induced disease does not
serve simply to accomplish the classic up-regulation of CD80/
CD86 but rather may up-regulate the expression of other molecules that may be required for the induction or regulation of
virus-induced disease—perhaps other cell surface “costimulatory” molecules and/or cytokines, including down-modulatory cytokines such as IL-10.
Here, based on initial microarray RNA expression profiling,
we address the possible role of the PD-1/PD-L1/PD-L2 and
IL-10 pathways in LP-BM5-induced disease. PD-1 (CD279), a
transmembrane protein belonging to the CD28/CTLA4 subfamily, was originally identified in a T-cell line undergoing
apoptotic cell death (30). PD-1 is generally thought to direct
inhibitory functions, but unlike that of CTLA-4, with which it
shares 23% amino acid homology, PD-1 expression can be
induced not only in T cells but also in B cells and certain other
cell types (25, 52). The PD-1 molecule contains an extracellular
immunoglobulin V (IgV)-like domain and cytoplasmic immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based switch motif domains. Antigen-stimulated
expression of PD-1 is followed by recruitment of tyrosine phosphatase src homology 2 domain-containing tyrosine phosphatase 2 to the immunoreceptor tyrosine-based switch motif,
but not to the immunoreceptor tyrosine-based inhibitory motif,
site (51, 53, 62). Two PD-1 ligands—PD-L1 (CD274) and
PD-L2 (CD273)—have been described, and both are type 1
transmembrane proteins containing IgV- and IgC-like domains
(18, 39). Both negative and positive effects on T-cell activation
have been reported following PD-1 ligation by PD-L1 and
PD-L2 (13, 15, 18, 39). PD-L1, constitutively expressed by T
and B cells, macrophages, and dendritic cells (DC), is additionally upregulated after activation, unlike PD-L2 expression,
which is much less prevalent and present mainly on activated
macrophages and DC (15, 72). Both ligands are also found on
tumor cells from various tissue and organ sites (13, 16, 67).
Although many direct and indirect mechanisms of action have
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been suggested following PD-1 ligation, of special note to the
present investigation, it has been reported that in vitro activation strategies such as anti-CD3 and PD-L1 stimulation result
in increased secretion of IL-10 (15, 38, 68). IL-10 has also
recently been shown to induce the expression of PD-L1 on
monocytes (64, 65) and to be a key player in acute versus
chronic lymphocytic choriomeningitis virus (LCMV) infection
(7, 17). In general (not relating to primarily IL-10 studies),
several reports have detailed the role of the PD-1/PD-L pathway in mouse and human viral diseases such as hepatitis C and
HIV-induced AIDS (5, 14, 31, 55, 69, 70).
MATERIALS AND METHODS
Mice. Seven-week-old male B6 mice were purchased from the National Institutes of Health (Bethesda, MD), housed in the Dartmouth Medical School
Animal facility, and used when 8 to 10 weeks of age. Breeding pairs fully
backcrossed to B6 IL-10 KO mice obtained from The Jackson Laboratory (Bar
Harbor, ME) were originally derived as previously described (36). B6-backcrossed PD-1 KO breeding pairs derived as reported previously (50) were obtained from Jian Zhang Rush-Presbyterian-St. Luke’s Medical Center, Chicago,
IL. B6.Rag-1 KO mice purchased from The Jackson Laboratory were employed
as recipients in adoptive-transfer experiments in which equal numbers were
reconstituted with purified CD4⫹ T and B cells from various donor mice.
Splenocyte subpopulation preparation. For cellular reconstitution of Rag-1
KO mice, splenocyte suspensions were labeled with anti-CD19 (1D3)- or antiCD4 (L3T4)-coupled paramagnetic beads and subjected to column purification
according to the manufacturer’s (MACS; Miltenyi Biotec, Auburn, CA) protocol. Purified B-cell populations were obtained by incubation with anti-CD19
beads, positively selecting for CD19⫹ B cells, and subsequently the flowthrough
cells were labeled with anti-CD4 beads, positively selecting for CD4⫹ T cells.
These selection approaches yielded cell preparations which were ⱖ98% B220⫹
or ⱖ90% CD4⫹ enriched, respectively, as detected by flow cytometric analyses.
LP-BM5 virus inoculations. LP-BM5 was prepared in our laboratory as previously described (33). G6 cells, originally generously provided by Janet Hartley
and Herbert Morse (NIH affiliation), a cloned cell line from SC-1 cells infected
with the LP-BM5 virus mixture, were used in a coculture with uninfected SC-1
cells to produce LP-BM5 virus stocks. As noted in Results, mice were infected
intraperitoneally with 1 ⫻ 105, 5 ⫻ 104, 2 ⫻ 104, or 3 ⫻ 102 ecotropic PFU as
determined by a standard retroviral XC plaque assay (60).
ELISA determinations of serum immunoglobulins. To measure serum hyperIg, capture antibodies, affinity-purified goat anti-mouse IgG2a or IgM (Southern
Biotechnology Associates, Birmingham, AL), were used to coat 96-well plates
after which enzyme-linked immunosorbent assays (ELISAs) were conducted as
previously described (21, 22, 23, 41, 42). The averages of experimental groups
were statistically compared by the Student t test.
Spleen cell response to mitogens. Spleen cells (4 ⫻ 105) from control and
experimental mice were plated in triplicate into 96-well plates with medium
containing 5% fetal calf serum, L-glutamine, antibiotics, and a final concentration
of 2 g/ml ConA or 10 g/ml LPS. After 72 h, all wells were pulsed with 1 Ci
of [3H]thymidine (Dupont NEN, Boston, MA) and harvested (Packard, Meriden, CT) 6 h later for assessment of thymidine incorporation by scintillation
counting (Packard, Meriden, CT). The averages of experimental groups were
statistically compared by the Student t test.
In vivo MAb blocking. Ascites preparations were obtained for the following
MAbs: anti-PD-1 (J43; reference 1), anti-PD-L1 (1 to 111A; reference 29), and
anti-PD-L2 (54S; reference 29). A dose of 100 l was administered intraperitoneally to LP-BM5-infected B6 mice three times a week for either 3 or 7.5 weeks
as indicated in Results.
Flow cytometry. For extracellular staining, 5 ⫻ 105 spleen cells were incubated
with fluorescein isothiocyanate (FITC)-, phycoerythrin-, allophycocyanin (APC)-, or
Cy-Chrome-conjugated antibodies, followed by direct immunofluorescence, as
quantified by log amplification (FACScalibur flow cytometer; BD Bioscience). To
detect the expression of the following murine antigens, the MAbs in parentheses
were employed: CD4 (L3T4), CD8a (Ly2), CD19 (1D3), CD23 (FCεR11), CD11b
(Mac-1a), CD16/CD32 (Fc␥ II/III receptor), CD11c (HL3), PD-1 (J43), PD-L1
(M1H5), and PD-L2 (TY25) (BD Pharmingen). Appropriate FITC-, phycoerythrin-,
APC-, or Cy-Chrome-conjugated Ig isotypes of irrelevant specificity were used to
control for each experimental MAb. Intracellular cytokine staining (ICCS) of IL-10
was performed by incubating 1 ⫻ 106 spleen cells for 5 h with complete medium, 5
U/ml IL-2, and 5 g/ml brefeldin A (Sigma). After washing with phosphate-buffered
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TABLE 1. Microarray RNA expression profiling of LP-BM5-infected B6 mice at 3.5 wpi
Description

Accession no.

Fold
increasea

Melanoma antigen, endogenous ecotropic murine
leukemia provirus region
Murine (DBA/2) fragment for gag-related peptide
Monokine induced by IFN-␥

D10049

10.24

X05546
M34815

2.66
2.67

LP-BM5-induced hyper-Ig

Germ line IgG1 gene, D-J-C region; 3⬙ exon for
secreted form

V00793

3.78

Unknown role in LP-BM5 infection

PD-1
IL-10

X67914
M37897

2.39
8.22

Function

Generalized infection related

a

Values indicate gene expression in infected B6 mice divided by that in uninfected B6 mice.

saline, extracellular staining for cell surface markers was first performed as described
above and then the cells were fixed in 2% formaldehyde and permeabilized with
0.5% saponin, followed by intracellular staining with FITC–anti-IL-10 MAb JES516E3. All stained cells were analyzed on a FACScalibur flow cytometer using
CellQuest software (BD Bioscience).
Microarray RNA expression profiling. Total RNA was isolated from spleen
cells from LP-BM5-infected and uninfected mice using RNeasy kits (Qiagen,
Valencia, CA). Subsequent microarray experiments were conducted at the Norris Cotton Cancer Center Microarray Shared Resource at Dartmouth Medical
School. All procedures, including RNA preparation, hybridization, washes, and
analysis using the Affymetrix Murine Genome Array u74A, were conducted
according to the manufacturer’s (Affymetrix, Inc., Santa Clara, CA) directions.
RNA isolation and real-time quantitative reverse transcription (RT)-PCR.
Viral load was determined for BM5def and BM5eco as previously described (12,
20, 24, 41, 42). Briefly, total RNA was isolated from spleen tissue using TriReagent (Molecular Research Center, Cincinnati, OH) and treated with a DNAfree kit (Ambion, Austin, TX). Following RT and amplification of cDNA (BioRad iScript cDNA synthesis kit), PCR was performed using iQ SYBR green
Supermix and iCycler software (Bio-Rad, Hercules, CA).

RESULTS
Expression of PD-1, PD-L1, and PD-L2 in uninfected versus
LP-BM5-infected C57/BL6 mice. To gain further insight into
possible inhibitory molecular pathways involved in LP-BM5induced disease, WT B6 mice infected with LP-BM5 were
sacrificed at 3.5 wpi, a point within the time span we had
previously defined by in vivo anti-CD154 MAb blocking experiments as critical for CD154/CD40 interactions and commitment to disease progression (21, 22). Utilizing splenic mRNA
obtained from these mice, mRNA expression profiling was
performed via an Affymetrix Murine Genome Array (see Materials and Methods) comparison of uninfected versus 3.5-wpi
samples as summarized in part in Table 1. Compared to uninfected mice, as expected, the following two classes of genes
were highly up-regulated in response to LP-BM5 infection: (i)
several commonly expressed sequences as a consequence of
LP-BM5 infection per se—e.g., mRNA corresponding to endogenous ecotropic murine leukemia proviral sequences (encoding a melanoma-associated retroviral antigen or a gag-related peptide), presumably cross-reactive with the LP-BM5
retrovirus also of endogenous derivation, and (ii) the germ line
IgG1 gene and other Ig-associated sequences, as indicators of
LP-BM5-induced hyper-Ig, which is an early activation disease
parameter first easily measurable at 3.5 wpi. In addition, other
genes without an obvious, or previously described, function in
LP-BM5-induced disease were also found to be highly expressed, including those encoding PD-1 and IL-10. Real-time

RT-PCR (12), using specific primers, confirmed the increased
levels of mRNA for both PD-1 and IL-10 in 3.5-week LP-BM5infected B6 mice, compared to uninfected control mice (data
not shown).
Flow cytometric analyses of spleen cells from 3.5- and 10week LP-BM5-infected B6 mice were performed to evaluate,
at the protein level, the relative cell surface expression of PD-1
(Fig. 1A), PD-L1 (Fig. 1B), and PD-L2 (data not shown). At
3.5 wpi, there was a trend toward increases in the percentages
of each of the CD4⫹, CD8⫹, CD19⫹, and CD11b⫹ cell subsets
expressing PD-1 (with that for CD4⫹ T cells of particularly
significance), compared to the low percentages of detectable
PD-1 for each of these subsets from uninfected mice. At 10
wpi, significant increases in PD-1 expression were observed in
all of these cellular subsets (Fig. 1A). Generally, only small, if
any, increases in the mean fluorescence intensity (MFI) were
detected for the PD-1-expressing cell populations at 3.5 wpi.
At 10 wpi, the MFI values were somewhat increased for all
subsets at about 1.5-fold that of analogous cells from the uninfected mice (Fig. 1 legend). Regarding PD-L1, all of the cell
subsets (Fig. 1B) appeared to exhibit LP-BM5 infection-dependent up-regulated expression at 3.5 wpi, although the increases in the percent positive cells were statistically significant
for only CD8⫹ T cells and CD19⫹ B cells, presumably in part
due to the widely expressed constitutive levels of PD-L1
(⬎90%) for each splenic cell subset from uninfected mice.
With regard to the MFI of PD-L1 expression, at both 3.5 and
10 wpi, the infection-dependent increases, if any, were relatively modest (i.e., twofold or smaller) for all cell subsets. Only
a small percentage of PD-L2⫹ cells was detectable, and only at
10 wpi with LP-BM5 and only for CD11b⫹ cells (data not
shown). Therefore, cell surface PD-1 protein was expressed at
substantially increased levels during LP-BM5-induced disease.
PD-L1 expression was also up-regulated above constitutive
levels as early as 3.5 wpi with LP-BM5, in contrast to PD-L2.
Thus, these collective results are consistent with the possibility
of an involvement of PD-1, and in particular PD-L1, in LPBM5-induced disease.
LP-BM5 retrovirus-infected PD-1 KO mice demonstrated
greatly enhanced pathogenesis compared to infected WT mice.
To evaluate LP-BM5-induced disease susceptibility, the following standard disease readouts, as previously described and
utilized by our and other laboratories (3, 8, 10, 11, 20–24, 26,
28, 41, 42, 47, 73, 74), were evaluated postinfection with LP-
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FIG. 1. Upregulated cell surface expression of PD-1 and PD-L1 by
spleen cells from LP-BM5-infected B6 mice. Spleen cells from noninfected mice (black bars) and WT B6 mice infected with 5 ⫻ 104 PFU
LP-BM5 at 3.5 wpi (light gray bars) and 10 wpi (dark gray bars) were
stained with MAbs directed to PD-1, PD-L1, or one of the listed cell
surface markers. Data shown are the percentages of cells positive for
PD-1 (A) or PD-L1 (B) among the total cells of each marker-defined
(i.e., CD4, CD8, CD19, or CD11b) subset. MFI values for the spleen
cell subsets from uninfected and LP-BM5-infected mice were, respectively, as follows: (3 wpi, PD-1⫹) CD4⫹, 16 and 19; CD8⫹, 15 and 15;
CD19⫹, 42 and 42; CD11b⫹, 20 and 16; (3 wpi, PD-L1⫹), CD4⫹, 17
and 34; CD8⫹, 18 and 31; CD19⫹, 67 and 67; CD11b⫹, 22 and 28; (10
wpi, PD-1⫹) CD4⫹, 39 and 60; CD8⫹, 34 and 55; CD19⫹, 29 and 47;
CD11b⫹, 33 and 50; (10 wpi, PD-L1⫹), CD4⫹, 26 and 43; CD8⫹, 24
and 41; CD19⫹, 24 and 35; CD11b⫹, 35 and 48. This pattern of results
was also observed in two other experiments. Significance levels: *, P ⬍
0.05; **, P ⬍ 0.01; ***, P ⬍ 0.001.

BM5: splenomegaly (spleen weight) and serum IgG2a concentration (as a measure of hyper-Ig)—both indicators of the early
activational aspects of disease; splenic B-cell responsiveness to
lipopolysaccharide (LPS) and T-cell responsiveness to concanavalin A (ConA) mitogen stimulation, as indicators of immune system functional status; and characteristic cell surface
marker-defined lymphoid subset prevalence. First, it was important to determine whether B6.PD-1 KO mice displayed
intrinsic phenotypic differences compared to WT B6 mice that
would complicate the assessment of disease by these parameters. However, this was not the case; B6.PD-1 KO versus WT
B6 uninfected mice had no statistically significant differences in
disease parameter baseline levels—e.g., spleen weight and serum IgG2a levels (Fig. 2), and their spleen cells responded
similarly to ConA and LPS mitogen stimulation. PD-1 KO
mice infected for 8 weeks with 2 ⫻ 104 PFU LP-BM5, a
somewhat limiting dose (see below), consistently demonstrated
a substantially greater degree of LP-BM5-induced disease by
all of the disease readouts examined, compared to WT mice
infected in parallel (Fig. 2A and B). For example, the average
spleen weight of the infected PD-1 KO mice exhibited a highly
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FIG. 2. B6.PD-1 KO mice are more susceptible to LP-BM5-induced disease than WT mice as a function of the viral dose. A somewhat limiting dose of 2 ⫻ 104 PFU of LP-BM5 virus was administered
to B6.PD-1 KO and WT B6 mice. At 8 wpi, viral pathogenesis was
assessed by splenomegaly (A), serum IgG2a levels (B), and the spleen
cell mitogenic response to LPS or ConA stimulation (C); the latter is
depicted as percent inhibition of the uninfected control LPS and ConA
responses. This pattern of results was also observed in one other
experiment. Significance levels: NS, P ⬎ 0.05; *, P ⬍ 0.05; **, P ⬍ 0.01.

significant (P ⬍ 0.001) approximately sevenfold increase, compared to uninfected KO spleen weight, whereas for WT B6
mice the increase was only about twofold. Similarly, the increase in serum IgG2a concentration for the infected PD-1 KO
mice was highly significant, approximately 15-fold, compared
to uninfected KO values, in contrast to only about a 2-fold
increase for infected versus uninfected WT mice. Consistent
with these results but in terms of immunodeficiency readouts,
the spleen cell mitogenic responses to LPS and ConA of PD-1
KO cells were essentially completely inhibited, whereas these
same responses of infected WT mice demonstrated only partial
immunodeficiency; the B-cell response to LPS was inhibited
62%, and the T-cell response to ConA was inhibited 74%.
PD-1 KO and WT mice were also infected with a lower, very
limiting dose of LP-BM5 (3 ⫻ 102 PFU) and were similarly
evaluated at 8 wpi for LP-BM5-induced disease (data not
shown). The average spleen size and serum Ig concentration of
PD-1 KO mice, albeit with considerable mouse-to-mouse variation, were both approximately fivefold higher than the average responses of uninfected KO mice versus only about a
twofold increase for infected WT mice. For the mitogen responses measuring the extent of immunodeficiency, the percent inhibition of responsiveness was partial (74% for LPS,
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48% for ConA), owing to the limited viral dose, for PD-1 KO
mice. However, substantially less immunodeficiency was observed in infected WT B6 mice—30% less than that of
B6.PD-1 KO mice.
Infection of B6.PD-1 KO and WT mice with a high dose 5 ⫻
104 PFU LP-BM5, relative to the experiments of Fig. 2, and
evaluation at the extended time point of 10 wpi for LP-BM5induced disease allowed assessment of whether (i) the absence
of PD-1 continued to simply magnify disease symptomatology,
irrespective of the viral dose, or (ii) the extent of the effect of
the KO of PD-1 on disease was ultimately limited. With this
increased dosage of virus and 2 additional weeks of infection,
infected PD-1 KO and WT mice had similar mean spleen
weights that were not significantly different (data not shown;
PD-1 KO mice, 650 mg; WT B6 mice, 720 mg) and both LPS
and ConA mitogenic spleen cell responses were completely
inhibited in both the KO and WT strains. The only disease
readout showing a substantial difference was that for serum
IgG2a, as a measure of hyper-Ig, with average values for PD-1
KO and WT B6 mice of 4.9 and 2.3 mg/ml, respectively.
As a function of time postinfection, LP-BM5-infected
B6.PD-1 KO mice develop greater retrovirus-induced pathogenesis than LP-BM5-infected WT B6 mice. We next examined
the question of whether infected B6.PD-1 KO mice displayed
more rapid kinetics of LP-BM5-induced disease compared to
WT B6 mice. As shown in Fig. 3A, as early as 3.5 wpi with 2 ⫻
104 PFU LP-BM5 virus, PD-1 KO mice developed significant
splenomegaly, with an average spleen weight about five times
the mean uninfected spleen weight. At this same early time
point postinfection, there was an insignificant increase in
spleen weight in WT LP-BM5-infected mice. At the standard
terminal 8 wpi, statistically significant (about fourfold) splenomegaly was observed, as expected for infected WT B6 mice,
but for infected PD-1 KO mice, much exaggerated disease was
observed—a highly significant increase of approximately 10fold. Indeed, there was a very clear reproducible difference in
the spleen weights of PD-1 KO versus WT B6 infected mice
when they were compared directly (P ⬍ 0.0001). Similarly, at
3.5 wpi (Fig. 3B), the average serum IgG2a concentration was
also much more significantly (P ⬍ 0.0001) elevated in LPBM5-infected PD-1 KO mice, at approximately 25-fold that of
uninfected values, than in infected WT mice (⬃10-fold). At 8
wpi, the PD-1 KO average serum IgG2a value was very exaggerated at ⬃200-fold that of uninfected KO mice, in contrast to
the increase in infected WT mice (⬃20-fold). Again, for both
3.5- and 8-wpi mice, as with the other activational disease
parameters, PD-1 KO mice demonstrated clearly enhanced
susceptibility to LP-BM5-induced retroviral disease.
In parallel, spleen cells from LP-BM5-infected PD-1 KO mice
are much more severely impaired at the early 3.5-wpi time point
in responding to stimulation with the B-cell mitogen LPS and the
T-cell mitogen ConA, with essentially complete inhibition of responses to both mitogens. In contrast, these same responses of
infected WT B6 mice were inhibited only 33% and 23% after LPS
and ConA stimulation, respectively (Fig. 3C). By 8 wpi, although
the inhibition of the WT response to ConA had caught up to the
continued nearly complete inhibition already observed for the
PD-1 KO mice at 3.5 wpi, the immunosuppression of the LPS
response continued to lag in these WT infected mice (68% inhibition). Thus, all of the disease parameters measured were con-
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FIG. 3. LP-BM5-infected B6.PD-1 KO mice have detectable LPBM5-induced disease as early as 3.5 wpi and exaggerated disease
compared to WT mice at 8 wpi. For PD-1 KO mice compared to B6
WT mice infected with 2 ⫻ 104 PFU LP-BM5 virus, virus-induced
disease was assessed by splenomegaly (A), serum IgG2a levels (B), and
the spleen cell mitogenic response to LPS or ConA stimulation (C);
the latter is depicted as percent inhibition of the uninfected control
response. This pattern of results was also observed in three other
experiments. Significance levels: *, P ⬍ 0.05; **, P ⬍ 0.01; ***, P ⬍
0.001.

sistent in demonstrating that the kinetics of LP-BM5-induced
immunodeficiency is greatly accelerated in B6.PD-1 KO, compared to WT B6, infected mice.
Infection of B6.PD-1 KO mice with LP-BM5 leads to more
pronounced changes in the spleen cell surface expression of
CD19 and CD11b. LP-BM5-induced pathogenesis in B6 mice is
closely associated with characteristic changes in the expression of
specific cell surface molecules that define various cell subsets,
including the presence of CD19⫹ CD23⫹ B cells and CD11b⫹
CD16/CD32⫹ (Fc␥R⫹) myeloid cells (20, 35). Our and other
laboratories have exploited these changes as additional quantitative measures of the extent of disease. Here, uninfected versus
infected (2 ⫻ 104 PFU) WT B6 and B6.PD-1 KO mice were
sacrificed at 3.5 or 8 wpi and spleen cells were evaluated by flow
cytometric analyses (Fig. 4A). As shown in the representative
experiment of Fig. 4A, in infected WT mice, as early as 3.5 wpi the
percentage of CD23⫹ CD19⫹ cells declined, but only slightly
(61% to 52% of all splenocytes), while this downward trend continued to 31% at 8 wpi. In sharp contrast, in infected PD-1 KO
mice a greatly accelerated decline from the uninfected level of
58% CD23⫹ CD19⫹ cells was observed, to only 22% at 3.5 wpi
and 17% at 8 wpi. In addition, and strikingly, the decline in the
percentage of total CD19⫹ (Fig. 4B) spleen cells in infected mice
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FIG. 4. B6.PD-1 KO mice develop more dramatic spleen cell phenotypic changes than WT B6 mice after LP-BM5 infection. B6.PD-1
KO and WT B6 mice were infected with 2 ⫻ 104 PFU LP-BM5 virus
and sacrificed at 3.5 or 8 wpi. Spleen cells labeled in two-color analyses
with MAb to cell surface markers CD23 and CD19 (A) or CD16/CD32
and CD11b (B) were analyzed on a FACScalibur flow cytometer. The
percentages of total CD19⫹ cells that are also CD23⫹ are shown in the
upper right quadrants of panel A, and the percentages of total CD16/
CD32⫹ cells that are also CD11b⫹ are shown in the upper right
quadrants of panel B. A log fluorescence scale was used. This pattern
of results was also observed in two other experiments.

was much sharper and complete in PD-1 KO mice—by 8 wpi, only
6% of the total splenocytes expressed detectable CD19, irrespective of CD23 expression. In terms of total splenic B-cell numbers,
in both WT and PD-1 KO infected B6 mice, there was an increase
by 3.5 wpi, due to the developing splenomegaly. However, this
enlargement of the spleens could not offset the dramatic decline
in the percentage of B cells in 8-week-infected PD-1 KO mice—
compared to uninfected mice, splenic B-cell numbers were decreased about fivefold. That this change represented an actual
loss of B cells, rather than a selective down-regulation of CD19
(as well as CD23), was supported by the corresponding lack of
B220⫹ cells (data not shown) and, as detailed below (in comments concerning Fig. 4B), CD11b⫺ CD16/CD32⫹ cells, the phenotype of essentially all conventional B cells.
Another spleen cell phenotypic change in LP-BM5-infected
mice involves an increase in CD11b⫹ CD16/CD32⫹ myeloid
spleen cells (Fig. 4B). In WT mice, this change was first readily
apparent at 8 wpi (22% of CD16/CD32⫹ cells are also
CD11b⫹, versus 14% for uninfected mice). However, in
B6.PD-1 KO mice, this phenotypic change was greatly exaggerated; at only 3.5 wpi, an ⬃3-fold increase was already evident and by 8 wpi, an ⬃6.5-fold increase was observed, with
71% of the CD16/CD32⫹ cells also expressing CD11b. As the
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CD16/CD32-defined Fc␥R is also expressed on essentially all
conventional splenic CD19⫹ B cells, the corresponding decrease in PD-1 KO mice of the CD16/CD32⫹ CD11b⫺ population was consistent with the above-noted decline in B cells as
defined as CD19⫹ (Fig. 4A). Indeed, in all cases the percentages of total CD19⫹ cells (CD23⫹ or CD23⫺) were very close
to that of this CD16/CD32⫹ CD11b⫺ population. Overall,
these results (i) confirmed the exaggerated nature of LP-BM5induced disease in PD-1 KO mice (by a disease parameter not
directly measuring function) and (ii) demonstrated a dramatic
(ⱖ80%) loss of splenic B cells compared to WT B6 mice.
B-cell expression of PD-1 is primarily involved in moderating LP-BM5-induced disease in WT B6 mice. PD-1 expression
therefore appears important in limiting the kinetics and extent
of LP-BM5-initiated disease. To approach the question of
which cellular subset(s) is required to express PD-1 to moderate the effects of LP-BM5-induced disease in WT mice, a set of
reciprocal adoptive-transfer experiments were undertaken by
using highly purified WT, versus PD-1 KO, donor CD4⫹ T and
B cells. Thus, B6.Rag-1 KO recipients were given intravenous
parallel transfers of four combinations of purified CD4⫹ T and
B cells, i.e., (i) WT B and CD4⫹ T cells, (ii) PD-1 KO B and
CD4⫹ T cells, (iii) WT B and PD-1 KO CD4⫹ T cells, and (iv)
PD-1 KO B and WT CD4⫹ T cells, by using essentially the
reconstitution protocol we previously used (23, 41, 42). Three
days later, a portion of the recipients were infected with LPBM5. At sacrifice at 10 wpi, all of the disease parameters
measured, including spleen weight, mitogen responsiveness as
a measure of immunodeficiency, and the phenotypic shift to
increased percentages of CD11b⫹ CD16/CD32⫹ cells, were
most pronounced (relative to the WT/WT control) under two
experimental conditions, (i) PD-1 KO B and PD-1 KO CD4⫹
T cells and (ii) PD-1 KO B and WT CD4⫹ T cells (Fig. 5). The
observation that LP-BM5-infected Rag-1 KO mice that had
previously received PD-1 KO B cells along with either WT or
PD-1 KO CD4⫹ T cells displayed the most disease strongly
suggested that it was the common lack of PD-1 expression on
B cells that was responsible for the exaggerated virus-induced
disease. Said another way, this reproducible pattern of results
clearly implied that in LP-BM5-infected WT B6 mice, B-cell
PD-1 expression was of primary importance in its moderation
of LP-BM5-induced disease.
In vivo blocking studies with anti-ligand MAbs to modulate
LP-BM5-induced disease in WT B6 mice. To determine which
of the PD-1 ligands, PD-L1 and/or PD-L2 (15, 72), might be
involved in the ligation of PD-1 to mediate the down-modulation
of virus-induced disease, the following experimental conditions
were defined: LP-BM5-infected WT B6 mice were treated in vivo
with anti-PD-1 MAb as a positive control for enhanced disease,
with anti-PD-L1 MAb, or with anti-PD-L2 MAb (see Materials
and Methods). Standard LP-BM5-induced disease readouts were
performed at either 3.5 or 8 wpi, including splenomegaly, hyperIg, and mitogen responsiveness/immunodeficiency (Fig. 6). At 3.5
wpi, spleen weight comparisons between uninfected B6 mice and
LP-BM5-infected mice without versus with antibody treatment
indicated that all infected mice had significant splenomegaly.
However, although the differences were not statistically significant, there was a trend toward more disease in both the anti-PD-1
(expected, as blocking PD-1 would be analogous to the use of
PD-1 KO mice) and anti-ligand (PD-L1 or PD-L2) MAb-treated
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FIG. 5. B-cell PD-1 expression is primarily involved in moderating
LP-BM5-induced disease in WT B6 mice. Rag-1 KO B6 mice were
reconstituted with purified cellular subsets obtained from either WT or
PD-1 KO donors, and 3 days after such adoptive transfer, recipients
were infected with 1 ⫻ 105 PFU LP-BM5 virus. At 10 wpi, all mice
were evaluated for disease severity by disease readouts measuring
either spleen size (A) or mitogen reactivity (B); the latter is depicted
as percent inhibition of the uninfected control response. The percentages of recipient CD11b⫹ cells that are CD16/CD32 at the time of
sacrifice are shown in panel C. This pattern of results was also observed in one other experiment. Significance level: *, P ⬍ 0.05.

mice (Fig. 6A). A similar pattern of results was obtained when
assessing the extent of LP-BM5-induced disease at 3.5 wpi by
means of the hyper-Ig and mitogen responsiveness readouts (Fig.
6B and C), with the suggestion of somewhat augmented disease
observed for either anti-PD-L1 or anti-PD-L2 (or anti-PD-1)
MAb-treated, infected mice, although again the differences were
not statistically significant compared to mice infected but not
receiving anti-PD-L MAb treatment. For example, the serum Ig
concentrations of anti-PD-1-, anti-PD-L1-, or anti-PD-L2-treated
mice at 3.5 wpi were all two- to threefold that of infected, untreated mice. In contrast, at 8 wpi, only those mice that were
LP-BM5 infected and treated with the anti-PD-L1 MAb consistently developed a substantially exaggerated, statistically significant degree of disease compared to infected but otherwise
untreated mice (e.g., spleen weight, P ⬍ 0.05; serum IgG2a, P ⬍
0.05) (Fig. 6A and B). This differential result for blocking by
anti-PD-L1 versus anti-PD-L2 MAb was observed for all disease
parameters, except for the single readout of responsiveness to the
B-cell mitogen LPS, where anti-PD-L2 treatment also led to enhanced hyporesponsiveness. Indeed, at 8 wpi, noting the different
y-axis scales for the splenomegaly and hyper-Ig parameters compared to 3.5 wpi (Fig. 6A and B), all disease readouts indicated
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that the largest absolute enhancement of viral pathogenesis was
observed following anti-PD-L1 treatment of LP-BM5-infected
mice.
In summary, these data confirm the results obtained with the
PD-1 KO mice (Fig. 2 to 5) and further suggest that, particularly for full disease measured at 8 wpi, PD-1-dependent moderation of virus-induced disease involves preferential ligation
of PD-1 by PD-L1.
B6.IL-10 KO mice also display exaggerated viral pathogenesis after LP-BM5 infection. Based on the expression-profiling
data on genes induced after LP-BM5 infection (Table 1) and
reports linking occupancy of PD-1 by PD-L1 and the production of IL-10 (15, 38, 65, 68), we next investigated whether
IL-10 might also be down-regulating disease in WT B6 mice.
IL-10 KO mice infected with 2 ⫻ 104 PFU LP-BM5, similar to
PD-1 KO mice given this same dose, exhibited a more exaggerated form of disease at 8 wpi, based on all measured disease
parameters, including splenomegaly, hyper-Ig, and mitogen responsiveness as an indication of immunodeficiency (Fig. 7).
For example, IL-10 KO mice developed an about sixfold increase, compared to uninfected spleen weight, whereas when
this same comparison was made for uninfected and infected
WT mice, a substantial but only about threefold increase in
spleen size was observed (Fig. 7A). The average increased
serum IgG2a level for infected IL-10 KO mice was also substantially higher, at approximately 130-fold, compared to an
⬃30-fold increase for WT mice infected in parallel. Similarly,
both the LPS and ConA mitogen responses of infected IL-10
KO mice were almost totally inhibited, while the inhibition of
the LPS and ConA responses was less pronounced in infected
WT mice (77% and 94%, respectively).
When B6 versus B6.IL-10 KO mice were infected instead
with the very limiting dose of 3 ⫻ 102 PFU LP-BM5, the same
pattern of exaggerated disease for IL-10 KO mice was observed (data not shown). For example, despite some mouseto-mouse variation (as expected at this low dose [see above]),
infected IL-10 KO mice had with an average spleen weight of
470 mg versus only 140 mg for WT mice infected in parallel.
Similarly, for average serum IgG2a values of infected mice, the
response, though considerably lower than at the 2 ⫻ 104 dose,
was substantial and noticeably skewed to more disease in the
IL-10 KO mice, with a mean value of 4 mg/ml versus 330 g/ml
for WT B6 mice. With respect to mitogen responsiveness, a
similar trend was observed, particularly for the ConA response, which was inhibited 88% in IL-10 KO mice versus only
43% inhibition in WT infected mice.
Thus, at two different virus doses, LP-BM5-infected B6.IL-10
KO mice, compared to WT mice, developed more severe splenomegaly, hyper-Ig, and immunodeficiency—a phenotype analogous to that of mice in which the PD-1 pathway was inhibited
either by use of PD-1 KO mice or via the anti-PD-1 or anti-PDL
MAb blocking approach.
LP-BM5-infected IL-10 KO mice were also more susceptible
than WT mice to LP-BM5-induced disease at the early time point
of 3.5 wpi, with a highly significant average spleen weight (P ⬍
0.001) of 380 mg (more than fivefold that of uninfected mice),
whereas there was a much smaller increase in the spleen weight of
infected WT mice, i.e., 177 mg (1.8-fold compared to uninfected
WT mice). Serum IgG2a levels followed the same pattern of
greater hyper-Ig in IL-10 KO mice (P ⬍ 0.001), with IL-10 KO
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FIG. 6. PD-L1, rather than PD-L2, appears to be the preferential ligand for PD-1 in LP-BM5-induced disease, at least at 8 wpi. WT B6 mice
were infected with 2 ⫻ 104 PFU LP-BM5 virus and given anti-PD-1, anti-PD-L1, and anti-PD-L2 MAbs intraperitoneally three times per week for
either 3 or 7.5 weeks. At the termination time point of 3.5 or 8 wpi, LP-BM5-induced disease was evaluated by spleen weight (A), serum IgG2a
ELISA (B), and mitogen response to LPS and ConA stimulation (C); the latter is depicted as percent inhibition of the uninfected control
responses. With respect to the data for spleen weights and serum IgG2a levels, at the 3.5 wpi time point, comparing the untreated and anti-PD-1,
anti-PD-L1, or anti-PD-L2 MAb-treated mouse groups, all comparisons were not statistically significant (P ⱖ 0.05). In contrast, at 8 wpi, the
untreated versus anti-PD-L1 MAb-treated comparison was significant (P ⬍ 0.05). All other comparisons were not statistically significant.
Significance levels: *, P ⬍ 0.05; **, P ⬍ 0.01.

mice averaging 3.1 mg/ml (⬎45-fold, compared to uninfected
mice) and WT mice 1.5 mg/ml (⬎25-fold compared to uninfected
mice, with one WT mouse not yet exhibiting obvious hyper-Ig).
The response to the T-cell mitogen ConA was also 90% inhibited
for IL-10 KO mice at 3.5 wpi versus a fully intact response for
infected WT B6 mice. IL-10 KO mice were also similar to infected PD-1 KO mice (Fig. 4) at 3.5 wpi with LP-BM5, as infection led to IL-10 KO spleen cell preparations that exhibited (i) a
trend toward an increase in CD11b⫹ CD16/CD32⫹ cells (a 33%
rise, borderline significant at P ⬍ 0.07) and (ii) a decrease in
CD19⫹ CD23⫹ B cells (an ⬃46% decline, P ⬍ 0.001).
Thus, based on these cumulative results and the mRNA
expression data in Table 1, it appeared that in WT LP-BM5-

infected B6 mice, as a consequence of IL-10 expression, viral
disease was decreased. As it is well known that a wide variety
of cell types are capable of secreting IL-10, it was of interest to
determine the identity of the cells responsible for IL-10 production in WT B6 mice following infection by LP-BM5 retrovirus. By ICCS analysis coupled with cell surface labeling with
MAbs directed to CD4, CD8, B220 (for B cells), CD11b (for
myeloid cells), and CD11c (for DC), ex vivo splenic cells were
assessed at both 3.5 and 8 wpi (Fig. 8). Compared to uninfected B6 mice, where the percentage of IL-10-producing cells
among these subsets was undetectable, except for 0.9% of
CD11b⫹ cells, LP-BM5 infection led to an increased percentage of IL-10 producers. Namely, ⬃4-fold (3.5 wpi, P ⬍ 0.05) to
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FIG. 7. IL-10 KO B6 mice are more susceptible to LP-BM5-induced disease than WT B6 mice. IL-10 KO and WT B6 mice were
infected with 2 ⫻ 104 PFU LP-BM5 and sacrificed at 8 wpi. Mice were
evaluated for splenomegaly, serum Ig levels, and spleen cell responses
to LPS and ConA; the latter is depicted as percent inhibition of the
uninfected control response. This pattern of results was also observed
in one other experiment. Significance level: *, P ⬍ 0.05.
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⬃5.4-fold (8 wpi, P ⬍ 0.001) expansions of IL-10-producing
cells were observed, and this occurred entirely within the
CD11b⫹ subset (Fig. 8). Based on the lack of a corresponding
increase among CD11c⫹ cells (Fig. 8), and given preliminary
experiments with anti-F4/80 staining, it appeared that macrophage or macrophage-like cells were primarily, if not solely,
responsible for the LP-BM5 induction of IL-10 production.
The results from Fig. 8, taken together with the very similar
exaggerated disease phenotypes of the IL-10 KO and PD-1 KO
strains following LP-BM5 infection, suggested that the PD-1
and IL-10 pathways might be linked mechanistically. As a first
approach toward testing this possibility, we also examined
IL-10 production in infected PD-1 KO mice. The CD11b⫹
macrophage-like population again appeared to be primarily, if
not solely, responsible for IL-10 production in PD-1 KO mice.
However, in contrast to B6 mice (Fig. 8), an LP-BM5 infectiondependent increase in the percentage of (CD11b⫹) cells producing IL-10 by ICCS analysis was not observed at either 3.5
wpi (P ⱖ 0.05) or 8 wpi (P ⱖ 0.05) (Fig. 9). This lack of
increased IL-10 production was underscored by the observation that the expansion of the CD11b⫹ macrophage-like population was even greater (about twofold) in the PD-1 KO,
compared to WT B6, infected mice (confirming the results of
Fig. 4). Similarly, when IL-10 expression was assessed instead
by enzyme-linked immunospot assay analysis, again, the LPBM5 infection-dependent increase in IL-10-secreting cells observed with WT B6 mice was not detected in PD-1 KO mice
(data not shown). Thus, the inability of LP-BM5-infected PD-1
KO mice to express increased IL-10 in the CD11b⫹ compartment was consistent with a “linear relationship” between PD-1

FIG. 8. LP-BM5 infection of WT B6 mice induces an increase of CD11b⫹ IL-10⫹ spleen cells. Spleen cells from uninfected WT B6 mice versus
LP-BM5-infected (2 ⫻ 104 PFU) WT B6 mice at 3.5 or 8 wpi were labeled with APC-conjugated MAbs to the indicated cell surface markers with
subsequent ICCS for IL-10 (see Materials and Methods). The labeled cells were analyzed on a FACScalibur flow cytometer using CellQuest
software (BD Bioscience). The significance levels for the percentage of CD11b⫹ IL-10⫹ spleen cells from infected versus uninfected mice were as
follows: 3.5 wpi mice, P ⬍ 0.05; 8 wpi mice, P ⬍ 0.001. This pattern of results was also observed in two other experiments.
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FIG. 9. LP-BM5 infection of PD-1 KO B6 mice does not induce an increase in CD11b⫹ IL-10⫹ spleen cells. Spleen cells from uninfected B6
mice versus LP-BM5-infected (2 ⫻ 104 PFU) PD-1 KO B6 mice at 3.5 or 8 wpi were labeled with APC-conjugated MAbs to the indicated cell
surface markers with subsequent ICCS for IL-10 (see Materials and Methods). The labeled cells were analyzed on a FACScalibur flow cytometer
using CellQuest software (BD Bioscience). The significance levels for the percentage of CD11b⫹ IL-10⫹ spleen cells from infected versus
uninfected mice were as follows: 3.5 wpi, P ⱖ 0.05; 8 wpi, P ⱖ 0.05.

and IL-10 in WT B6 mice. These results further suggested that
PD-1/PD-L ligation might be the basis for IL-10 production,
which then limits the extent of disease in infected B6 mice.
Viral load in infected WT, PD-1 KO, and IL-10 KO mice. To
determine if the exaggerated disease observed with LP-BM5infected PD-1 and IL-10 KO mice was simply due to an enhanced ability of the component retrovirus types to infect and
spread in these different hosts, compared to WT B6 mice, we
performed real-time, quantitative RT-PCR assays for both the
BM5def (pathogenic defective) and BM5eco (helper) retroviruses, as we have previously established (12). Although there
was some variation from experiment to experiment in the absolute levels of retroviral RNAs detected, in multiple analyses
we could find no evidence for any consistent differences in viral
load among B6 versus PD-1 KO versus IL-10 KO strains (data
not shown). A lack of significant difference in retroviral RNA
expression was observed at both 3.5 and 8 wpi. Thus, the
pronounced degree of disease in infected PD-1 and IL-10 KO
mice did not appear to be related to substantial differences in
BM5def or BM5eco expression.
DISCUSSION
The results of the present study highlight the fine balance of
T-cell responses in mediating protective immunity and also,
frequently, a substantial portion of the virus-induced immunopathogenesis that is characteristic of many viral infections.
Thus, especially in many chronic viral infections (e.g., lymphocytic choriomeningitis in mice; hepatitis B, hepatitis C, and

HIV/AIDS in humans; etc.), T-cell responses in particular, by
causing bystander tissue damage in an (often unsuccessful)
attempt to eradicate or contain the virus, constitute a doubleedged sword. If the virus or virus-infected cells cannot be
cleared entirely or quickly, a continuing source of viral antigen
often leads to dysregulated T-cell responses that are not fully
effective against the virus yet paradoxically are sufficient over
time to seriously damage host tissues.
Recently, in several chronic viral infection systems there
have been concerted efforts to boost protective T-cell responses. Rather than attempting to enhance antiviral T-cell
immunity by interventions focused on the cytokines and receptor-ligand pairs that promote the generation of specific CD8⫹
T cells (such as CD28:CD80/CD86, IL-12, etc., that mediate
costimulation), these new approaches have targeted negative
regulatory pathways. In particular, interruption of the ligation
of PD-1 on activated CD8⫹ (and CD4⫹ helper) T cells by
PD-L1 (PD-L2) has shown promise in stabilizing or reversing
the progressive CD8⫹ T-cell dysfunction characteristic of
chronic viral infections (e.g., see references 5, 14, 19, 31, 55, 65,
69, and 70). For example, in LCMV clone 13 (LCMV-13)
chronic infection in mice, in vivo MAb blockade of PD-1/PD-L1
interactions can at least partially circumvent the characteristic
exhaustion of the LCMV-specific CD8⫹ T-cell response (5).
Similarly, in humans the analogous exhaustion of the hepatitis C virus-specific CD8⫹ T-cell compartment was counteracted by anti-PD-L1 antibody treatment, and T-cell function
was thus restored (70). In addition, and as a retroviral infection
of particular relevance to the present study, a series of recent
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papers has provided evidence of a central role for PD-1/PDL-mediated down-modulation of the anti-HIV type 1 (HIV-1)
CD8⫹ T-cell response (14, 19, 55, 69). For example, in HIVseropositive individuals, activated CD8⫹ T cells directed to
HIV-1 (and other persisting viruses, notably, Epstein-Barr virus, which causes chronic virus infection[s]), but not those
specific for acutely infecting viruses such as vaccinia virus,
exhibited up-regulated PD-1 expression. In addition, levels of
PD-1 expression have been associated with decreased in vitro
proliferative responses of CD8⫹ T cells to HIV antigenic stimulation, decreased CD4⫹ T-cell counts, and increased viral
loads, suggesting that the degree of PD-1 expression correlates
directly with the severity of virus-induced disease (14). In vitro
approaches to block the ligation of PD-1 led to at least a partial
restoration of specific CD8⫹ T-cell numbers and functions, i.e.,
proliferation, lytic-component (granzyme B) expression, and
cytokine production (69). Conversely, using polyclonal antiPD-1 antibody in a cross-linked, presumably stimulatory, form
resulted in decreased HIV-1 antigen-specific T-cell proliferation (55).
The negative regulatory IL-10 cytokine has also received
much recent attention as a target for interventions to improve
protective antiviral immunity. For example, of particular relevance to the present discussion of chronic viral infections,
recent studies by two groups have identified a critical role for
the IL-10/IL-10R pathway in the LCMV-13 chronic infection
system (7, 17). First, IL-10 secretion is substantially increased
during this chronic infection, which presumably contributes to
the dysregulation of the protective CD8⫹ T-cell antiviral response. Second, by treating with a blocking anti-IL-10R antibody soon after infection of mice with LCMV-13 or by use of
IL-10 KO mice, the infection-dependent down-regulation of
LCMV-specific CD8⫹ (and CD4⫹) T-cell responses, including
gamma interferon (IFN-␥) and tumor necrosis factor alpha
production, was restored. Moreover, with interruption of the
IL-10/IL-10R pathway, viral titers were substantially reduced
and there was a timely resolution of the chronic infection.
Interestingly, in light of the possible intersection of the IL-10/
IL-10R and PD-1/PD-L negative regulatory pathways, anti-IL10R antibody treatment led to a substantial reduction in the
percentages of PD-1⫹ anti-LCMV-13-specific CD4⫹ and CD8⫹
T cells in chronically infected mice (17).
Positive effects on protective T-cell immunity can thus be
achieved by interfering with these negative regulatory pathways. An added benefit may be a concomitant decrease in virusinduced immunopathology. For example, in the LCMV-13 virus
chronic infection system, blocking the occupancy of PD-1 by specifically anti-PD-L1 MAb treatment restored CD8⫹ T-cell immunity and allowed better control of the virus without inducing
significant immunopathology (5). The chronic, relatively high viral antigen loads were thus decreased but not eliminated in all
tissues by anti-PD-L1 MAb treatment. Assuming that the antibody blocking was thus not complete, such a PD-1/PD-L1 partial
blockade may have been a prime factor in tipping the balance to
effective immunity yet with decreased immunopathology. Indeed,
total interruption of PD-1/PD-L1 interactions clearly exacerbated
pathogenesis in LCMV-13-infected mice; while WT mice developed the chronic form of the infection, PD-L1 KO mice died due
to overt immunopathology (5). These results underscore the key
involvement of PD-L1 (and, by implication, PD-1) in moderating
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immunopathological, as well as protective, antiviral immune responses.
In the LP-BM5 retroviral system described herein, loss of
PD-1 ligation, particularly by PD-L1, at 8 wpi also leads to
greatly enhanced viral pathogenesis (Fig. 2 to 4 and 5). We and
others have demonstrated that CD4⫹ T cells (and B cells) are
required for LP-BM5-induced disease (10, 23, 48, 73). Further,
as we have shown that CD4⫹ T cells must be able to express
CD154 to ligate B-cell CD40 to mediate LP-BM5-initiated
disease (21–23), this system illustrates that there is virus coopting of the immune system for viral pathogenesis and that
disease depends on CD4⫹ T effector cell-mediated direct or
indirect immunopathology.
Although our results thus have general similarity to the
LCMV-13 system, noteworthy differences appear to account
for our observations that interruption of PD-1/PD-L interactions or IL-10 production led only to exaggerated LP-BM5induced disease, with no evidence of enhanced protective immunity. First, in the prototypic susceptible B6 strain studied
here, we have no evidence for a protective CD8⫹ T-cell response. In disease-resistant BALB/c mice, however, we have
shown that CD8-deficient (chronic in vivo anti-CD8 MAb
treated or CD8 KO) mice convert to disease susceptibility (27,
45) and that WT BALB/c mice generate a strong antiviral
CD8⫹ T-cell response (63). Indeed, the BALB/c CD8⫹ T effector cells are highly lytic, secrete IFN-␥, and are protective
against LP-BM5 virus challenge in vivo, in terms of both inhibition of disease and the ultimate viral load, after their adoptive transfer into BALB/c. CD8 KO recipients (27, 44). Of
note, both the polyclonal and clonal CD8⫹ T-cell populations
that were protective were specific for a unique Kd-presented
immunodominant epitope, SYNTGRFPPL, which derives
from a previously unrecognized alternative (⫹1 nucleotide)
gag translational open reading frame of the LP-BM5 retrovirus
(44, 45). In contrast, the same immunization approaches with
LP-BM5 virus or viral gag vector expression systems were unable to raise LP-BM5 virus-specific CD8⫹ cytotoxic T lymphocytes in B6, BALB.B congenic, or other H-2b susceptible mice
(45, 63). Thus, in the apparent absence of evidence of even a
suboptimal protective CD8⫹ T-cell response in B6 mice, interruption of the PD-1 or IL-10 negative regulatory pathway
would not have been able to provide the beneficial effect of
augmented protective T-cell immunity to LP-BM5. Rather, in
contrast to the LCMV-13 and other chronic viral systems described above, release from PD-1 and IL-10 negative control
should only have been able to increase the strength of the
immunopathogenic CD4⫹ T-cell response.
A second difference in LP-BM5-infected B6 mice, compared
to the reports on the positive effects of PD-1/PD-L1 blockade
in LCMV and other chronic virus systems, is the nature of the
cell type that critically expresses PD-1. Whereas the focus in
these chronic virus systems was on PD-1 expression by the
protective CD8⫹ (or CD4⫹) T cells, the present cell subset
fractionation and reconstitution experiments identified B-cellexpressed PD-1 as crucial for the normal down-modulation of
LP-BM5-induced immunopathogenesis in WT B6 mice (Fig.
5). Our identification of B cells as the most relevant cells for
PD-1 expression and consequent regulation of the extent of
LP-BM5-induced disease is consistent with numerous reports
indicating the central role of B cells in this retroviral immu-
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nodeficiency model (10, 20, 23, 33, 34, 40, 54, 74). The mechanism of this B-cell-dependent, PD-1-mediated inhibition of
LP-BM5-induced disease is unclear. One possibility is a direct
effect on B cells in which PD-1-initiated negative signaling or
apoptosis of B cells limits disease. If B-cell apoptosis per se is
the relevant mechanism, however, in PD-1 KO mice, a higher
percentage of B cells would be predicted, not the substantially
lower percentages observed after LP-BM5 infection (Fig. 4).
Alternatively, enhanced B-cell survival in PD-1 KO mice might
not lead to an accumulation of conventional B cells but rather
allow, via the extended B-cell life span, for their enhanced
further differentiation into “effector B cells”—e.g., memory B,
preplasma, and/or plasma cells. This possibility is in keeping
with the massive hyper-Ig observed especially in LP-BM5-infected PD-1 KO mice (Fig. 2 and 3). In addition, a favored
interpretation of our previous (20) finding that CD154-ligated
B-cell CD40 signaling occurs primarily, if not exclusively,
through TRAF6—i.e., that LP-BM5 virus-induced disease is
minimal in B6.CD40-TRAF6 binding site mutant mice—is that
B effector cells are necessary for this retrovirus-mediated disease. Thus, to our knowledge, the only obvious immunological
phenotype of these B6.CD40 KO background mice, which express a transgenic chimeric CD40 (human external and mouse
transmembrane and cytoplasmic domains) with a mutated
TRAF6 site, is a dramatically reduced plasma cell compartment and a related relative inability to produce class-switched
IgG1 antibody responses to antigenic stimulation (2).
As a related mechanistic consideration, it is useful to compare the results here of the disease phenotypes of B6 mice
infected with LP-BM5 in the context of the absence of the
PD-1/PD-L versus the IL-10 negative regulatory pathway. Because the ultimate outcome of greatly exaggerated disease is so
similar (Fig. 2 and 3 versus 7), it is tempting to speculate that
interruptions of these two pathways fundamentally cause the
same mechanistic effect and that the PD-1/PD-L and IL-10
pathways are “linearly” arranged. Along these lines, it may be
noteworthy that we obtained a preferential effect of blocking in
vivo with anti-PD-L1, compared to anti-PD-L2, MAb, at least
at 8 wpi (Fig. 6). There is evidence in several other systems that
“reverse” signaling through PD-L can occur upon PD-1/PD-L
interactions and that APC stimulation through PD-L1/PD-L2
can result in IL-10 production (6, 38, 71). Similarly, in the
LP-BM5 retroviral model used here, ICCS analysis demonstrated that IL-10 production could largely, it not entirely, be
ascribed to a CD11b⫹ CD11c⫺ CD16/CD32 (Fc␥R)⫹ F4/80⫹
macrophage/macrophage-like population (Fig. 8 and data not
shown). Given that macrophages express PD-L1 and that an
expanded population of CD11b⫹ CD16/CD32⫹ cells develops
in WT B6 mice in an infection-dependent manner (Fig. 1 and
4), such IL-10 production could result from (B-cell) PD-1
occupancy of PD-L1 on these macrophage-like cells. In support of this possibility, in infected PD-1 KO mice, although the
expansion of these CD11b⫹ macrophage-like cells was even
greater than that in infected WT B6 mice, no infection-dependent increase in IL-10 production by this subset was observed
by either ICCS (Fig. 9) or enzyme-linked immunospot assay
analysis. Thus, PD-1 expression was required for the increased
IL-10 response, and further studies are required to confirm
whether such IL-10 production in WT B6 mice is triggered by
binding of specifically PD-L1 to PD-1.
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However, other interpretations are possible and clarification
of this question awaits additional and challenging experiments
required to differentiate these possibilities. These and other
issues raised by the results presented here underscore the
utility of the LP-BM5 retroviral system for the further study of
the effects of blockade of the PD-1/PD-L and IL-10 negative
regulatory pathways on antiviral T-cell-mediated immunopathology and provide a cautionary note relative to attempts to
enhance protective T-cell immunity in viral diseases where
such T cells also cause tissue damage.
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